Breast Cancer
Conditions
Brief summary
Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.
Interventions
PROCEDURENeoadjuvant chemotherapy
Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
PROCEDUREAdjuvant chemotherapy
Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
Sponsors
Seoul National University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 100 Years
Inclusion criteria
* Patients who underwent breast-conserving surgery for invasive breast cancer between 2004 and 2018
Exclusion criteria
* Total mastectomy * No pre- or postoperative chemotherapy * No radiation therapy * Bilateral breast cancer * Male breast cancer patients * Secondary breast cancer * Metachronous or synchronous cancers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Locoregional recurrence-free survival (LRR) | Defined as the time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of LRR, assessed up to 120 months | Time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of locoregional recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Distant metastasis-free survival | Defined as the time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of distant metastasis, assessed up to 120 months | Time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of distant metastasis |
Countries
South Korea
Outcome results
None listed